Pharma Medical News about FDA

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA Approves Boston Scientifics TAXUS Liberte Long Stent
Boston Scientific, 07/17/09

Boston Scientific Corporation announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS Liberte Long Paclitaxel–Eluting Coronary Stent System, a next–generation drug–eluting stent (DES) designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can potentially reduce the number of stents used in more complex cases, simplifying procedures and reducing costs.

<< Previous
Prepare Now to Avoid the Burn

Next >>
Morphotek, Inc. and Cancer Innovations, Inc. Announce Evaluation...

Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma
Journal of Clinical Endocrinology and Metabolism, 11/12/09 Relevance Score: 89%

A brave new beef: The US food and drug administrations review of the safety of cloned animal products
Gender Medicine, 10/26/09 Relevance Score: 89%

FDA Steps Up Efforts to Find, Remove Violators of Clinical Trial Regulations
JAMA, 10/28/09 Relevance Score: 87%

Angiotech Pharmaceuticals Provides Update on Bio-Seal™ 510(K) Submission
Angiotech Pharmaceuticals, 10/20/09 Relevance Score: 87%

The FDA Reviews Safety of Stimulant Medication for ADHD
American Journal of Nursing, 10/01/09 Relevance Score: 87%